Darolutamide vs Abiraterone Side Effect Comparison for 18-Month Therapy

Clinical Context: Treatment Indication

The National Comprehensive Cancer Network recommends systemic hormonal therapy with ADT as the foundation for metastatic castration-sensitive prostate cancer (M1a disease with pelvic lymph node involvement) 1, 2, 3
Both darolutamide and abiraterone are appropriate intensification options when combined with ADT for metastatic hormone-sensitive disease 4, 5

Abiraterone requires mandatory prednisone co-administration and intensive monitoring due to mineralocorticoid excess, including monthly monitoring of liver function tests, serum potassium, phosphate levels, and blood pressure 6
Abiraterone's mineralocorticoid-related effects include hypertension, hypokalemia, and fluid retention, requiring mineralocorticoid receptor antagonist consideration 6
The use of abiraterone is associated with a higher risk of hyperglycemia, weight gain, and bone loss due to chronic steroid exposure 5
Darolutamide demonstrates superior tolerability with minimal unique toxicities, including lower discontinuation rates due to adverse events compared to placebo in clinical trials 6
Darolutamide has a lower fatigue incidence than placebo, suggesting minimal impact on quality of life 6
Darolutamide does not require corticosteroid co-administration, avoiding all glucocorticoid-related side effects 5

Abiraterone is associated with a 37% risk reduction in pain intensity progression 6
Abiraterone is associated with a 53% reduction in fatigue compared to ADT alone 6
Abiraterone is associated with a 15% reduction in overall QOL deterioration 6
Darolutamide has a favorable tolerability profile with lower adverse event burden 6
Darolutamide has minimal impact on daily functioning due to lack of corticosteroid requirement 1

The National Comprehensive Cancer Network recommends monitoring bone density in patients with prostate cancer, as ADT accelerates bone loss 3, 7
The use of abiraterone is associated with an increased risk of cardiovascular events and metabolic syndrome due to its mineralocorticoid effects (hypertension, fluid retention) 7
Darolutamide is a single agent that does not require prednisone or potential antihypertensives and potassium supplementation, reducing polypharmacy burden 6

The National Comprehensive Cancer Network recommends against using abiraterone without corticosteroids without careful monitoring and readiness to add mineralocorticoid receptor antagonist 6
The National Comprehensive Cancer Network recommends monitoring bone density regardless of agent chosen, as ADT itself accelerates bone loss 3, 7
The National Comprehensive Cancer Network recommends assessing cardiovascular risk factors before initiating either therapy, given ADT's metabolic effects 3, 7

The National Comprehensive Cancer Network recommends initiating continuous ADT (LHRH agonist/antagonist) as Category 1 recommendation for M1a disease 1, 2, 3
The National Comprehensive Cancer Network recommends adding darolutamide for systemic intensification given its superior tolerability profile, no corticosteroid requirement, reduced monitoring burden, and lower cardiovascular/metabolic risk in elderly patients 1, 6, 7